Commentary|Videos|October 24, 2024
Long-Term Data for CPX-351 in Secondary AML
Author(s)Harry Erba, MD, PhD, James K. McCloskey, MD
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5